Demand for Novo Nordisk’s Wegovy pill surged immediately after UK approval, with a major online pharmacy reporting a waiting list of about 30,000 people per week. The report highlights how access bottlenecks can emerge in parallel with new product launches, even before longer-term supply and reimbursement dynamics fully play out. For biotech leaders watching obesity therapeutics, the episode reinforces that oral weight-loss formats can quickly amplify demand signals across markets.